EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.

Autor:	Delgado Sillero I; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Lopetegui Lia N; Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland OH, USA., Sánchez Cousido LF; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Rojas Piedra M; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Távara Silva B; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Garrido Onecha ML; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Medina Valdivieso S; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Alonso Horcajo N; Department of Anatomic Pathology, University of Leon Health Center complex, Leon, Spain., Díez Tascón C; Department of Anatomic Pathology, University of Leon Health Center complex, Leon, Spain., López González A; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Castañón López C; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Pedraza Lorenzo M; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., García Palomo A; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain., Martín V; University of Leon, Leon, Spain., Diz Tain P; Department of Medical Oncology, University of Leon Health Center complex, Leon, Spain.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Jun; Vol. 29 (4), pp. 854-860. Date of Electronic Publication: 2022 Mar 21.
DOI:	10.1177/10781552221085253
Abstrakt:	Introduction: 10-16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those treated with platinum-based chemotherapy (CT) doublets. Our aim is to perform a real-world survival analysis of patients treated with TKI as first-line therapy at the Hospital of Leon (CAULE) in Spain. The impact on global survival rates and responses to clinical and histopathological factors were also analyzed. Material and Methods: We retrospectively reviewed patients diagnosed with EGFR-mutated NSCLC who received treatment with EGFR-TKI in the Department of Oncology at the University of Leon Health Center complex between March 2011 and June 2018. Data was analyzed with Kaplan-Meier and Cox regression models to show overall survival (OS), progression-free survival (PFS), and the associated variables. Results: 53 patients were included in the study, 50% (n = 27) were treated with gefitinib, 32% (n = 18) with erlotinib and 10% (n = 6) with afatinib. The median OS and PFS were 27.7 months (95% CI: 21-33.8 months) and 18 months (95% CI 14.25-21.89 months), respectively. The variables associated with OS and with PFS were exon19 deletion as a protective factor and presence of extrathoracic metastasis as a risk factor. The most frequent adverse effects were rash, diarrhea, asthenia, and conjunctivitis. Conclusions: Real-world analysis of this data confirms that treatment with TKI is beneficial for patients diagnosed with EGFR-mutated NSCLC. Our OS outcomes were similar to those reported in clinical trials.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu